Related Experiment Video
Updated: Jul 14, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Reduced Dose-Direct Oral Anticoagulant Vs Dual Antiplatelet Therapy After Left Atrial Appendage Closure in Patients
Anurag Jha1, Nirmal Paudel2, Mohammad Azeem Malik1
1King Edward Medical University, Lahore, Pakistan.
Insights
Reduced-dose direct oral anticoagulants (DOACs) after left atrial appendage closure (LAAC) significantly reduced thromboembolic events and major bleeding compared to dual antiplatelet therapy (DAPT). Apixaban-based regimens showed the strongest benefit, supporting their consideration in selected patients.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- Nonvalvular atrial fibrillation (NVAF) management often involves left atrial appendage closure (LAAC).
- The use of reduced-dose direct oral anticoagulants (DOACs) post-LAAC is increasing, but comparative effectiveness against dual antiplatelet therapy (DAPT) is unclear.
Purpose of the Study:
- To assess the efficacy, safety, and net clinical benefit of reduced-dose DOACs versus DAPT following percutaneous LAAC in NVAF patients.
- To compare thromboembolic events, bleeding complications, and mortality between the two therapeutic strategies.
Main Methods:
- A systematic review and meta-analysis of 7 studies (3 RCTs, 4 cohorts) involving 2126 patients.
- Included patients received reduced-dose DOACs (apixaban 2.5 mg BID or rivaroxaban 10-15 mg QD) or DAPT post-LAAC.
- Outcomes were pooled using random-effects models, assessing heterogeneity with I² and Chi² statistics.
Main Results:
- Reduced-dose DOAC significantly decreased composite thromboembolic events (RR=0.20), ischemic stroke (RR=0.33), and device-related thrombosis (RR=0.33) versus DAPT.
- Net clinical benefit favored reduced-dose DOAC (RR=0.36), with apixaban subgroups showing the most significant reduction.
- Major bleeding (RR=0.54) and any bleeding (RR=0.52) were significantly lower with reduced-dose DOAC; mortality rates did not differ.
Conclusions:
- Reduced-dose DOAC therapy post-LAAC is associated with lower thromboembolic events and major bleeding compared to DAPT.
- Apixaban-based regimens demonstrated particularly strong benefits.
- These findings support the consideration of reduced-dose DOACs in appropriately selected NVAF patients after LAAC.
Background:
Reduced-dose direct oral anticoagulants (DOACs) are increasingly used after left atrial appendage closure (LAAC) in nonvalvular atrial fibrillation (NVAF), but their benefit over dual antiplatelet therapy (DAPT) remains uncertain.
Objective:
To evaluate the efficacy, safety, and net clinical benefit of reduced-dose DOAC versus DAPT following percutaneous LAAC in adults with NVAF.
Methods:
A systematic review and meta-analysis of randomized controlled trials and observational cohorts comparing reduced-dose DOAC (apixaban 2.5 mg twice daily or rivaroxaban 10-15 mg once daily) with DAPT after successful LAAC in adults (≥18 years) with NVAF was conducted by searching PubMed, Embase, Scopus, Cochrane CENTRAL, and ClinicalTrials.gov from inception through February 2026. Dichotomous outcomes were pooled as risk ratios (RRs) with 95% confidence intervals (CIs) using random-effects models; heterogeneity was assessed with I² and χ² statistics. Analyses were performed with RevMan 5.4.
Results:
Seven studies (3 randomized controlled trials, 4 cohorts) including 2126 patients (reduced-dose DOAC = 1088; DAPT = 1038) were analyzed. Reduced-dose DOAC significantly reduced composite thromboembolic events (RR = 0.20, 95% CI = 0.10-0.39; I² = 0%), ischemic stroke (RR = 0.33, 95% CI = 0.13-0.80; I² = 0%), and device-related thrombosis (RR = 0.33, 95% CI = 0.18-0.60; I² = 0%) compared with DAPT. The net clinical benefit composite (thromboembolism plus major bleeding) favored reduced-dose DOAC (RR = 0.36, 95% CI = 0.19-0.70; I² = 63%), with apixaban-predominant subgroups showing strongest effects (RR = 0.14, 95% CI = 0.05-0.36). Major bleeding was lower (RR = 0.54, 95% CI = 0.35-0.83; I² = 0%), any bleeding reduced (RR = 0.52, 95% CI = 0.30-0.88; I² = 64%), and minor bleeding trended lower (RR = 0.66, 95% CI = 0.42-1.02; I² = 34%), whereas cardiovascular (RR = 0.66, 95% CI = 0.23-1.92) and all-cause mortality (RR = 0.74, 95% CI = 0.42-1.30) did not differ significantly between groups.
Conclusion And Relevance:
Reduced-dose DOAC therapy after LAAC lowered thromboembolic events, device-related thrombosis, and major bleeding versus DAPT, without affecting mortality. These findings support consideration of reduced-dose DOACs, especially apixaban-based regimens, in appropriately selected patients.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:27Coronary Artery Disease V: Interprofessional Care
01:25Aortic Regurgitation III: Medical Management